US delay for Medeva drug
Medeva received a blow to near-term earnings prospects when US regulators requested additional information on Hepagene, a hepatitis B vaccine for which the emerging pharmaceutical company has great
Medeva received a blow to near-term earnings prospects when US regulators requested additional information on Hepagene, a hepatitis B vaccine for which the emerging pharmaceutical company has great